Importantly, while our primary patient and in vitro data points towards a similar RAS clonal selection across patients harboring the three MPN driver mutations, the majority of our validation experiments were conducted within a JAK2V617F mutational context and further experimental data is required to more precisely evaluate the interaction between RAS and CALR/MPL mutations. This evidence concerns the gene MPL and myeloproliferative neoplasm.